BMY Trading Analysis - 10/23/2026 04:10 PM — TRU-SENTIMENT

News Headlines & Context

The following items are based on general knowledge and are separated from the data-driven analysis below:

• Bristol Myers Squibb (BMY) recently announced positive Phase 3 results for a cardiovascular asset, reinforcing its pipeline beyond legacy oncology drugs.
• The company declared a quarterly dividend of $0.63 per share with an ex-dividend date of October 2, 2026, supporting its ~4.1% yield.
• BMY faced mild sector pressure as large-cap pharma recalibrated ahead of Q3 earnings season; no major negative catalyst reported.
• Analysts have noted BMY's low beta (0.19) as defensive appeal amid broader market volatility.
• Context: The upbeat pipeline narrative aligns with the bullish options sentiment in the embedded data, though technicals remain mixed.

Fundamental Analysis

Based strictly on the provided FUNDAMENTALS data:

• Trailing P/E is 13.60 with trailing EPS of $4.55; valuation appears modest versus typical pharma peers, though PEG ratio is null (not available).
• Dividend yield is 4.09% with annual rate of $2.52 and ex-dividend date 2026-10-02; fifty-two week range is $42.52 to $68.64.
• Market cap is $126.11B with 2.04B shares outstanding; institutional ownership is 56.51%.
• Beta is 0.19 (very low volatility vs market); historical volatility is 29.42%.
• Revenue growth, profit margins, ROE, debt/equity, and free cash flow are null in the data — not available for trend analysis.
• Forward P/E, target mean price, and analyst consensus are null; no analyst target context provided.
• Fundamentals show defensive yield and low beta, but absent growth/margin data creates divergence from technical indecision and bullish options flow.

Current Market Position

Current price per indicators is $63.08 (2026-10-22 close). Minute bars show 2026-10-22 open at $61.46 and intraday high $63.59; last bars on 2026-10-23 closed at $61.74 after ranging $61.56–$61.74. Recent daily history: 30-day high $65.29 (2026-09-14), low $56.15 (2026-10-13). Price is mid-range, above SMA_5 ($60.92) and SMA_20 ($60.51) but below SMA_50 ($63.27). Intraday momentum on 2026-10-23 was flat-to-slightly-up (last 5 bars: $61.60 → $61.74).

Technical Analysis

SMA_5 ($60.92) is above SMA_20 ($60.51) indicating short-term uptrend, but both are below SMA_50 ($63.27) showing medium-term downtrend pressure. RSI at 55.52 is neutral-positive, no overbought. MACD (-0.54) below signal (-0.43) with negative histogram (-0.11) = mild bearish momentum. Bollinger: middle $60.51, upper $64.34, lower $56.68; price $63.08 is near upper band (expansion). 30-day range: price is 74% up the range ((63.08-56.15)/(65.29-56.15)).

True Sentiment Analysis (Delta 40-60 Options)

Options flow (Delta 40-60 only) shows Bullish sentiment. Call dollar volume $385,134 (78.6%) vs put $105,159 (21.4%); 1,032 call contracts vs 287 put. Total analyzed $490,293. Pure directional conviction is strongly call-weighted.

Notable divergence: Options bullish but technicals show no clear direction (per spread recommendation: "Divergence detected between technical indicators and options sentiment"). This suggests near-term upside expectations not yet confirmed by price trends.

Key Price Levels (Observational Only)